You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD70

Showing 1 - 25 of 4,091
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CD70-positive Advanced Urologic Tumors Trial in Shanghai (Anti-CD70 CAR-T cells)

Recruiting
  • CD70-positive Advanced Urologic Neoplasms
  • Anti-CD70 CAR-T cells
  • Shanghai, Shanghai, China
    Changhai Hospital
Aug 11, 2023

Lymphoma Trial in Beijing (CD70-targeting CAR-T cells)

Recruiting
  • Lymphoma
  • CD70-targeting CAR-T cells
  • Beijing, Biotherapeutic Department Of Chinsese PLA Gereral Hospital, China
    China
Jul 9, 2023

Solid Tumor, Adult Trial in Beijing (CD70-targeting CAR-T cells)

Recruiting
  • Solid Tumor, Adult
  • CD70-targeting CAR-T cells
  • Beijing, Iotherapeutic Department Of Chinsese PLA Gereral Hospital, China
    China
Jul 8, 2023

Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer Trial in Nanchang (CD70 CAR-T cells)

Recruiting
  • Renal Cell Carcinoma
  • +4 more
  • CD70 CAR-T cells
  • Nanchang, Jiangxi, China
    The First Affiliated Hospital of Nanchang University
Aug 23, 2023

Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma Trial in Zhengzhou (CD70 CAR-T cells)

Recruiting
  • Metastatic Tumor
  • +4 more
  • CD70 CAR-T cells
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jul 19, 2022

Glioblastoma Trial in Gainesville (Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells)

Not yet recruiting
  • Glioblastoma
  • Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
  • Gainesville, Florida
    University of Florida Health
Jul 29, 2022

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

Recruiting
  • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
  • dualCAR-NK19/70 cell
  • Shanghai, Shanghai, China
    Shanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023

B-cell Non Hodgkin Lymphoma Trial in Hanzhou (CB dualCAR-NK19/70)

Not yet recruiting
  • B-cell Non Hodgkin Lymphoma
  • CB dualCAR-NK19/70
  • Hanzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Dec 25, 2022

Cancer Disease Trial in Shenzhen (bi-4SCAR PSMA/CD70 T cells)

Recruiting
  • Cancer Disease
  • bi-4SCAR PSMA/CD70 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma Trial in Jinan (CD70 CAR-T cells)

Recruiting
  • Metastatic Tumor
  • +4 more
  • CD70 CAR-T cells
  • Jinan, Shandong, China
    The Second People's Hospital of Shandong Province
Jun 14, 2022

Kidney Cancer, Lymphomas, Positron Emission Tomography Trial in Shanghai ([18F]RCCB6 PET Imaging)

Recruiting
  • Kidney Cancer
  • +2 more
  • [18F]RCCB6 PET Imaging
  • Shanghai, China
    Huashan Hospital
Nov 19, 2023

Cancer Disease Trial in Shenzhen (bi-4SCAR GD2/CD70 T cells)

Recruiting
  • Cancer Disease
  • bi-4SCAR GD2/CD70 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Metastatic Tumor, Renal Cell Carcinoma, Advanced Cancer Trial in Jinan (CD70 CAR-T cells)

Recruiting
  • Metastatic Tumor
  • +2 more
  • CD70 CAR-T cells
  • Jinan, Shandong, China
    The Second People's Hospital of Shandong Province
Jun 26, 2022

Acute Myeloid Leukemia, Non-hodgkin's Lymphoma, Multiple Myeloma Trial in Hangzhou (CD70 CAR T-cells)

Recruiting
  • Acute Myeloid Leukemia
  • +2 more
  • CD70 CAR T-cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Oct 26, 2021

B Cell Malignancies Trial in Shenzhen (bi-4SCAR CD19/70 T cells)

Recruiting
  • B Cell Malignancies
  • bi-4SCAR CD19/70 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 28, 2022

Leukemia, Relapsed, Myeloid Trial in Netherlands, Switzerland (MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123

Recruiting
  • Leukemia
  • +3 more
  • MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70)
  • Amsterdam, Netherlands
  • +4 more
Jan 4, 2023

Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma Trial in Nashville (CTX131)

Recruiting
  • Clear Cell Renal Cell Carcinoma
  • +4 more
  • CTX131
  • Nashville, Tennessee
    Research Site 1
Mar 21, 2023

Tumors Trial in Belgium, France (ARGX-110)

Completed
  • Neoplasms
  • Brussel, Belgium
  • +7 more
Aug 5, 2021

T Cell Lymphoma Trial in Australia, Canada, United States (CTX130)

Recruiting
  • T Cell Lymphoma
  • CTX130
  • Duarte, California
  • +9 more
May 16, 2022

Gastric Cancer, Colon Cancer, Rectal Cancer Trial in Taiyuan (CEA-targeted CAR-T cells)

Recruiting
  • Gastric Cancer
  • +6 more
  • CEA-targeted CAR-T cells
  • Taiyuan, Shanxi, China
  • +1 more
Aug 24, 2023

Gastric Cancer, Colon Cancer, Pancreas Cancer Trial in Nanchang (CEA CAR-T cells)

Recruiting
  • Gastric Cancer
  • +6 more
  • CEA CAR-T cells
  • Nanchang, Jiangxi, China
    The First Affiliated Hospital of Nanchang University
Aug 23, 2023

Tumor Trial (IMM40H)

Not yet recruiting
  • Tumor
  • (no location specified)
Sep 20, 2022

Allergy Trial in Worldwide (SQ tree SLIT-tablet, Placebo)

Recruiting
  • Allergy
  • SQ tree SLIT-tablet
  • Placebo
  • Vienna, Austria
  • +83 more
Dec 21, 2022

Parkinson's Disease Trial in Worldwide (IPX066, IR CD-LD)

Completed
Has Results
  • Parkinson's Disease
  • Birmingham, Alabama
  • +72 more
Aug 7, 2020

SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma Trial in Taiyuan (CD19 targeted CAR-T cells)

Recruiting
  • SLE (Systemic Lupus)
  • +4 more
  • CD19 targeted CAR-T cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Sep 25, 2023